• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Insulet Corporation

    2/5/26 1:28:07 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care
    Get the next $PODD alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 11)


    INSULET CORP

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    45784P101

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    45784P101


    1Names of Reporting Persons

    FMR LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6,135,772.03
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    6,306,853.90
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,306,853.90
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    45784P101


    1Names of Reporting Persons

    Abigail P. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    6,306,853.90
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,306,853.90
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    INSULET CORP
    (b)Address of issuer's principal executive offices:

    100 NAGOG PARK,ACTON,MA,USA,01720
    Item 2. 
    (a)Name of person filing:

    FMR LLC
    (b)Address or principal business office or, if none, residence:

    245 Summer Street, Boston, Massachusetts 02210
    (c)Citizenship:

    Not applicable
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    45784P101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    6306853.90
    (b)Percent of class:

    9.0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Please see the responses to Items 5 and 6 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    6306853.90

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of INSULET CORP. No one other person's interest in the COMMON STOCK of INSULET CORP is more than five percent of the total outstanding COMMON STOCK.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See attached Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FMR LLC
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
    Date:02/04/2026
     
    Abigail P. Johnson
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
    Date:02/04/2026

    Comments accompanying signature:  * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Exhibit Information

    Please see Exhibit 99 for 13d-1(k) (1) agreement.

    Get the next $PODD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PODD

    DatePrice TargetRatingAnalyst
    1/27/2026$294.00Hold
    TD Cowen
    1/12/2026$274.00Overweight → Equal Weight
    Barclays
    12/16/2025$370.00Outperform
    Evercore ISI
    11/19/2025$400.00Neutral → Buy
    UBS
    10/21/2025$370.00Buy
    Stifel
    9/8/2025$365.00Outperform
    Oppenheimer
    6/16/2025$365.00Buy
    Truist
    5/30/2025$380.00Buy
    Goldman
    More analyst ratings

    $PODD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen resumed coverage on Insulet with a new price target

    TD Cowen resumed coverage of Insulet with a rating of Hold and set a new price target of $294.00

    1/27/26 8:46:58 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet downgraded by Barclays with a new price target

    Barclays downgraded Insulet from Overweight to Equal Weight and set a new price target of $274.00

    1/12/26 8:59:23 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on Insulet with a new price target

    Evercore ISI initiated coverage of Insulet with a rating of Outperform and set a new price target of $370.00

    12/16/25 9:28:48 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care

    The Omnipod 5 Automated Insulin Delivery System is now commercially available in Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates, compatible with Abbott and Dexcom continuous glucose sensors Inaugural launch of Omnipod Discover data management platform aims to lessen the burdens on healthcare providers and users, streamlining diabetes information into meaningful insights Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its transformative Omnipod 5 Automated Insulin Delivery (AID) System is now available in the Middle East – including Saudi Arabia, Kuwait, Q

    2/5/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the fourth quarter and full year of 2025 on February 18, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic caller

    1/9/26 6:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Redefines Diabetes at CES with "Liveable Technology" — A New Frontier in Human-Centered Connected Health

    The Company will host a Digital Health Track panel discussion exploring how human-first design and intelligent automation are transforming chronic care into everyday freedom Insulet's immersive booth will showcase how tubeless, automated insulin delivery transforms the lives of people with diabetes by reducing mental load and improving health outcomes Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its debut at Consumer Electronics Show (CES) 2026, where the Company will showcase its vision for liveable technology through an immersive booth experience, expert panel s

    1/6/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Reg, Quality & Compliance Cousin Laetitia covered exercise/tax liability with 140 shares, decreasing direct ownership by 4% to 3,750 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    1/6/26 4:40:11 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Huffines Robert Luther was granted 51 shares, increasing direct ownership by 11% to 528 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    1/6/26 4:38:45 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Frederick Wayne A.I. sold $542,510 worth of shares (1,851 units at $293.09), decreasing direct ownership by 46% to 2,158 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    12/16/25 4:04:04 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Insulet Corporation

    SCHEDULE 13G/A - INSULET CORP (0001145197) (Subject)

    2/5/26 1:28:07 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - INSULET CORP (0001145197) (Filer)

    2/3/26 4:38:30 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - INSULET CORP (0001145197) (Filer)

    12/19/25 4:07:20 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stonesifer Timothy C. bought $299,884 worth of shares (962 units at $311.73), increasing direct ownership by 27% to 4,591 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    12/8/25 4:02:55 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    EVP, CFO & Treasurer Chadwick Ana Maria bought $20,600 worth of shares (100 units at $206.00), increasing direct ownership by 0.76% to 13,314 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    8/29/24 4:17:26 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Singh Prem bought $169 worth of shares (1 units at $168.92), increasing direct ownership by 0.02% to 4,032 units

    4 - INSULET CORP (0001145197) (Issuer)

    9/21/23 4:48:23 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Leadership Updates

    Live Leadership Updates

    View All

    Insulet Announces Appointment of Robert L. Huffines to its Board of Directors

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Robert ("Robbie") L. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase & Co., to the Company's board of directors, effective October 31, 2025. Mr. Huffines joins the board as an independent director and will serve on the board's Audit Committee. "We are honored to welcome Robbie to Insulet's Board of Directors," said Timothy Scannell, Chairman of the Board. "Robbie brings more than three decades of distinguished experience advising healthcare companies at one of the world's leading f

    10/23/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet to Host Investor Day on November 20, 2025

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's Acton, Massachusetts headquarters on Thursday, November 20, 2025. The Investor Day will include presentations from the management team highlighting the Company's longer-term strategic priorities, including market opportunities, innovation roadmap, as well as its longer-term financial outlook. Manufacturing tours will be available following the conclusion of the formal presentations, which are expected to begin at 9:00 a.m. (ET) and conclude at approximately 12:30 p.m. (ET). The Company invites in

    10/10/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Announces CFO Transition

    Flavia Pease Appointed Chief Financial Officer Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Flavia Pease will succeed Ana Maria Chadwick as Executive Vice President, Chief Financial Officer, effective September 30, 2025. Ms. Chadwick will become a Senior Advisor to Insulet to ensure a smooth transition. "I want to personally thank Ana, who has provided steady and thoughtful leadership for Insulet during a period of significant growth," said Ashley McEvoy, Insulet President and Chief Executive Officer. "She has been instrumental in strengthening our financial

    9/16/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Insulet Corporation

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    11/12/24 12:53:28 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Insulet Corporation

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    10/7/24 11:37:08 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Insulet Corporation (Amendment)

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    2/13/24 5:06:23 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $PODD
    Financials

    Live finance-specific insights

    View All

    Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the fourth quarter and full year of 2025 on February 18, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic caller

    1/9/26 6:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Reports Third Quarter 2025 Results

    Raises Full Year Revenue and Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2025. Third Quarter Financial Highlights: Revenue of $706.3 million, increased 29.9%, or 28.2% in constant currency1, and exceeded the high end of the Company's guidance range of 22% - 25% at constant currency rates Total Omnipod revenue of $699.2 million, rose 31.0%, or 29.3% in constant currency U.S. Omnipod revenue of $497.1 million, grew 25.6% International Omnipod revenue of $202.1 million, advanced 46.5%,

    11/6/25 6:30:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)

    Raising Full Year Revenue and Adjusted Operating Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2025. Second Quarter Financial Highlights: Revenue of $649.1 million, up 32.9%, or 31.3% in constant currency, exceeds the high end of the Company's guidance range of 26.0% in constant currency Total Omnipod revenue of $639.0 million, up 33.0%, or 31.4% in constant currency U.S. Omnipod revenue of $453.2 million, up 28.7% International Omnipod revenue of $185.8 million, up 45.0%, or 38.8% in cons

    8/7/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care